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Like a circus performer in a high-
wire act, the human immune system 
teeters on a precarious perch. It 
must continually balance an effective 
defense against microbial invaders 
with the need to avoid the kind of 
inappropriate immune activity that 
leads to autoimmune disease. The 
consequences of a misstep can be 
disastrous.
Natural killer T (NKT) cells, a 
specialized type of T cell, constitute 
one of the fulcrums upon which a 
functional and appropriate immune 
response balances. Although present 
in very small numbers in the body, 
NKT cells can produce large amounts 
of cytokines, thereby potently 
manipulating the activities of other 
cells of the immune system. However, 
the precise role of NKT cells in the 
immune response is unclear; in some 
circumstances, the cytokines made 
by NKT cells can prod a developing 
immune response into high gear 
to help fight off microbial invaders 
and cancer. But in other cases, NKT 
cells help prevent autoimmunity by 
strengthening immunosuppressive 
pathways. A better grasp of the 
functions of these enigmatic cells is 
essential to understanding the workings 
of the immune system.
One important question about NKT 
cells concerns the nature of the signals 
that are used in the body to regulate 
their development and function. 
NKT cells respond to glycolipids 
presented to them by other body 
cells (the glycolipids are presented in 
complexes with the CD1d protein, a 
relative of the major histocompatibility 
complex, [MHC] protein family). 
But just which glycolipids regulate 
NKT cell activity within the body? 
So far, the search for endogenous 
glycolipids that can activate NKT 
cells has turned up just one major 
contender: isoglobotrihexosylceramide 
(iGb3). This lipid is present in mice 
and can potently activate both mouse 
and human NKT cells. However, the 
role of iGb3 in NKT cell activation 
is a controversial subject, because 
not all research has supported the 
involvement of iGb3. Now, in this issue 
of PLoS Biology, Dale Christiansen, 
Mauro Sandrin, and colleagues deal a 
major blow to the importance of iGb3 in 
NKT cell activation by showing that the 
enzyme responsible for its synthesis—
iGb3 synthase (iGb3S)—is neither 
expressed nor functional in humans.
In their article, Christiansen et al. 
describe their efforts to determine 
whether iGb3 is an endogenous ligand 
for human NKT cells. Another research 
group had earlier thrown doubt on 
the importance of iGb3 when they 
were unable to detect iGb3 in mouse 
or human thymus (a major organ 
of the immune system). Therefore, 
Christiansen and colleagues first looked 
to see if they could find the mRNA for 
iGb3S in human tissues using reverse-
transcriptase (RT)-PCR. They could 
not detect iGb3S mRNA in any of the 
human tissues tested, although the 
possibility remained that the RT-PCR 
assay was not sufficiently sensitive to 
detect the mRNA if it were expressed 
at very low levels. This prompted the 
researchers to examine whether human 
iGb3S mRNA would be functional if it 
were expressed.
To determine whether human 
iGb3S has enzymatic activity, the 
group replaced the catalytic domain 
of rat iGb3S with that from the human 
sequence. They then expressed this 
hybrid protein in a cell line and looked 
to see whether it could synthesize iGb3. 
While normal rat iGb3S efficiently 
makes iGb3, the human–rat hybrid 
protein failed to make any iGb3 at all. 
Furthermore, changing just two amino 
acids in the rat iGb3S sequence to the 
ones found in the analogous positions 
of the human version was sufficient to 
completely inactivate the rat enzyme. 
The authors concluded that even if 
a protein product were made from 
the human iGb3S gene, it would 
likely be inactive due to the presence 
of multiple mutations. Collectively, 
these data show that humans lack the 
enzyme that is thought to be required 
to make iGb3. This finding challenges 
the idea that iGb3 has any role in 
the development or maintenance of 
human NKT cell populations. While 
the agonist properties of iGb3 for 
NKT cells is not in dispute and further 
studies into the significance of this 
molecule as an NKT cell ligand are 
warranted, it is becoming increasingly 
clear that the search for the 
endogenous glycolipid NKT ligand(s) 
must be re-started if we are to gain a 
better understanding of this cell type 
and its role in controlling the balance 
of immune function.
The absence of iGb3 in humans 
has other important physiological 
implications, beyond the control of 
NKT cells. For example, Christiansen 
and colleagues showed that humans 
actually make antibodies to iGb3 
(presumably because iGb3 is not 
normally present in the body) and 
that these antibodies can cause the 
lysis of cells that express iGb3. This is 
potentially important for the field of 
transplantation biology, which has been 
increasingly looking to our mammalian 
cousins as potential sources for organ 
transplantation. For example, pigs 
can be genetically manipulated to be 
more similar to transplant recipients. 
However, because pigs express iGb3 and 
humans do not, any organs transplanted 
from pigs to humans might face 
antibody or NKT cell-mediated attacks 
against the iGb3 antigen.
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New evidence casts doubt on a role for 
glycolipid iGb3 (structure pictured above) 
in regulating natural killer cells in the 
human immune system.